Mar 01,2022

DarioHealth Enters into Strategic Agreement with Sanofi U.S.

The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario's full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario's sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new or enhanced solutions leveraging the Dario platform, and for the parties to generate robust evidence to support future commercialization in the health plan channel.   

COLLABORATION PARTNERSHIP

#r&d

#dtx

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth Quarter 2021 Results: Total revenue for the fourth quarter was $4.0 million compared to $3.9 million for the fourth quarter of 2020.

View Analyst & Ambassador Comments
Go to original news
Mar 01,2022

DarioHealth Announced Pricing of its Registered Direct Offering for Aggregate Proceeds of $40 Million Priced At-The-Market Under Nasdaq Rules

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that on February 28, 2022 it entered into definitive agreements with institutional investors, including insurance companies located in Israel and primarily consisting of existing shareholders, in connection with a registered direct offering, providing for the issuance of an aggregate of approximately 5,342,013 shares of its common stock at a price of $7.49 per share.

View Analyst & Ambassador Comments
Go to original news
Mar 02,2022

OneTouch Verio Flex® Tops the Forbes Health Best Standard Glucose Meters of 2022 List, Just Announced, Highlighting the Meter’s ColorSure® Technology

LifeScan, a world leader in blood glucose monitoring, announced that its OneTouch Verio Flex®, the blood glucose meter that takes the guesswork out of your numbers so you can get on with life, was just rated Best Standard Glucose Meters Of 2022 by Forbes Health.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Mar 02,2022

Dexcom wins FDA breakthrough nod for use of its CGM in hospitals

Dexcom (NSDQ:DXCM) announced that it received FDA breakthrough device designation for the use of its CGM in a hospital setting. The FDA early in the COVID-19 pandemic issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 03,2022

Better Therapeutics Sponsors Educational Symposium on the Use of Software as a Next-Generation Treatment for Cardiometabolic Diseases

Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in collaboration with MedEd On The Go, today announced the availability of an on-demand, educational symposium entitled, “Next Generation Therapeutics for Cardiometabolic Diseases: Using Software Instead of Drugs.”

View Analyst & Ambassador Comments
Go to original news
Mar 03,2022

The Worldwide Insulin Patch Pumps Industry is Expected to Reach $1.7 Billion by 2027

The Global Insulin Patch Pumps Market size was estimated at USD 872.89 million in 2020 and expected to reach USD 957.82 million in 2021, at a CAGR of 10.16% to reach USD 1,718.71 million by 2027.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 07,2022

Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program (ADP) for people in the province living with type 1 diabetes who are over 2 years of age and meet coverage criteria.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 07,2022

Tandem Diabetes Care Announces Upcoming Virtual Conference Presentation

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 10:00am Eastern Time (7:00am Pacific Time).

View Analyst & Ambassador Comments
Go to original news
Mar 07,2022

DarioHealth to Participate in the Cowen 42nd Annual Healthcare Conference

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that management will participate in the Cowen 42nd Annual Healthcare Conference, which is being held virtually on March 7-9, 2022.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES